Technology

R2 compliance, central monitoring and RBM made simple! OPRA is the leading platform for anyone wishing to oversee quality,…

Read More

Consulting

Everything you need in order to achieve ICH E6 (R2) compliance, central and risk-based monitoring. TRI have now supported…

Read More

Training

At TRI we understand that successful implementation of ICH E6 (R2) and Risk-based monitoring is not just about processes…

Read More

It’s all about you

It’s a fact. Your trial is unique.  While it may have characteristics similar to other studies, by definition there has to be features that are unique to your trial, not least the patients, sites, timing and protocol.  That’s why you can’t commoditise trial quality.

Traditional monitoring practices are poor at identifying quality issues. Over 10% of failed submissions are due to data quality or integrity.  What if you could design trial quality in right from the start? And what if you could continue to manage that quality to drive your trial to a successful conclusion?

Well now you can.  We can help you design the optimal data for your clinical trial, guiding you through the centralized monitoring process to ensure your trial is fully R2 compliant. We provide the tools, training and support you need to identify and address risk early, saving you time and money, but more importantly, ensuring data quality, operational efficiency and patient safety.

Our approach is different.  It’s focused on what’s important to your trial. It’s practical and it’s operational. Our platform helps you quickly identify areas of quality risk and the likely causes of that risk, enabling you to manage that risk early. We don’t believe in meaningless statistics and data visualisation. In a world of big data, it’s still people that have to make decisions. Let us guide you to the right ones. 

TRI – Custom trials by data design. Get in touch today to see how we can help your trial.

 

Latest News

13 January
Free webinar – A change management framework for RBM – 31st Jan

Overcoming organisational resistance and implementing change relating to RBM and R2 compliance are the two biggest challenges…

6 January
COO’s Blog

Removing resistance to RBM one protocol risk assessment at a time …   Jan 6th 2019:  In…

15 November
The evolution of RBM – Duncan’s reflections from the CBI RBM conference

The evolution of RBM – reflections on CBI’s RBM event, November 2018  It’s always interesting going to…

8 November
Veristat partners with TRI

Veristat Partners with TRI to Provide Centralized and Risk-Based Monitoring Technology to Their Biopharmaceutical Clients Veristat, a…

Testimonials